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Abstract 
Subject: Recent studies have shown that smoking and drinking are associated with poorer outcomes in patients 
with cardiomyopathy. The purpose of this study was to determine all-cause mortality in dilated cardiomyopathy 
(DCM) associated with smoking and drinking.
Methods: An observational cohort study was undertaken in DCM patients from November 2003 to September 
2011. A total of 1118 patients were enrolled, with a mean follow-up of 3.5 ± 2.3 years. Standard demographics were 
obtained, and transthoracic echocardiography and routine blood testing were performed shortly after admission. 
Outcome assessment was based on the all-cause death after admission.
Results: The patients were divided into three groups: non-smokers (n = 593), mild-to-moderate smokers (n = 159) 
and heavy smokers (n = 366). The all-cause mortality rates showed no differences between the three groups (23.8, 
20.8 and 24 %, respectively; log-rank χ2 = 1.281, P = 0.527). There was also no significant difference in mortality 
between non-drinkers (n = 747), mild drinkers (n = 142) and moderate drinkers (n = 229) (23.7, 23.2 and 22.3 %, 
respectively; log-rank χ2 = 2.343, P = 0.310). In the Cox analysis, neither the smoking (HR 0.971, P = 0.663) nor the 
drinking status (HR 0.891, P = 0.140) was a significant independent predictor of all-cause mortality in patients with 
DCM.
Conclusion: In conclusion, there were no significant differences in mortality between the smoking- and drinking-
related patient groups, indicating no effect of smoking and drinking on all-cause mortality in patients with DCM in 
the present large-scale study.
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Background
Dilated cardiomyopathy (DCM), a disease of the heart 
muscle characterized by ventricular dilatation and 
impaired systolic function, is the third most common 
cause of heart failure [1, 2]. The prognosis of patients 
with DCM is poor, with approximately half of the patients 
dying within 5 years of diagnosis, and it is necessary for 
the physician to predict which clinical course an individ-
ual patient may follow [1, 2].
Studies in mice and humans have shown that alcohol 
is a direct myocardial toxin that causes ultrastructural 
damage. Heavy drinking has been associated with left 
ventricular dysfunction and DCM, referred to as alco-
holic cardiomyopathy [3, 4]. According to most studies, 
heavy drinking is associated with increased cardiovas-
cular morbidity and mortality [5–7]. The US National 
Health and Nutrition Examination has stated that alco-
hol consumption has a linear relationship with mortality, 
with a slightly higher mortality risk for even light drink-
ing [6, 7]. However, some studies have shown that mod-
erate alcohol consumption has cardioprotective effects; 
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reduces the risk of chronic heart failure, coronary artery 
disease and stroke; and decreases cardiovascular and all-
cause mortality [8–12].
Cigarette smoking is a major modifiable risk factor for 
cardiovascular diseases, including coronary artery dis-
ease, stroke, peripheral vascular disease and congestive 
heart failure [13, 14]. Both smoking and exposure to pas-
sive smoke are major preventable causes of cardiovas-
cular morbidity and mortality [15, 16]. Previous studies 
have indicated that smoking is related to cardiomyopathy 
[17] and is an important risk factor for idiopathic conges-
tive cardiomyopathy [18]. However, recent studies have 
suggested that patients with DCM who smoke have a bet-
ter prognosis than that of nonsmokers [19–21], although 
data from New Zealand show that smoking is associated 
with poorer survival in patients with DCM [22].
Although heavy drinking and smoking are known risk 
factors for cardiovascular mortality, their roles in DCM 
patients remain unclear [5, 19–22]. Therefore, in the pre-
sent study, we aimed to evaluate the association of drink-
ing and smoking with all-cause mortality in hospitalized 
patients with DCM in China.
Subjects and methods
Patients and follow‑up
A retrospective, observational cohort study of DCM 
patients was conducted from November 2003 to Septem-
ber 2011. The patients were admitted with symptoms of 
decompensation and physical signs of heart failure, and 
DCM was defined as systolic dysfunction (LVEF ≤50 %) 
with LV dilation in the absence of an apparent second-
ary cause of cardiomyopathy [23]. Of the 1317 enrolled 
patients, 175 patients were excluded from the study 
owing to the presence of various secondary cardiomyo-
pathies, and data on smoking and drinking were lack-
ing for 24 and 25 patients, respectively (Fig.  1). Thus, 
the final analysis included 1118 patients, with data on 
drinking lacking for 1 patient. The end point of the study 
was the all-cause mortality, which was assessed for all 
patients based on medical records and medical follow-up 
calls. Mortality data were obtained for all study patients 
from hospitalization to death. Data from patients who 
underwent cardiac transplantation were censored at the 
time of transplantation, if alive, to the date of the most 
recent clinical evaluation. The mean follow-up was 
3.5 ± 2.3 years. The institutional review board approval 
was obtained.
Smoking and drinking habits
The three categories of drinkers were: non-drinkers; mild 
drinkers, who reported drinking an average of one drink 
a day on the days on which they consumed alcohol during 
the previous year; and moderate drinkers, who reported 
drinking an average of two drinks a day on the days on 
which they consumed alcohol during the previous year (1 
drink =  12  g alcohol) [24]. Three categories of smokers 
were considered: non-smokers, mild-to-moderate smok-
ers, who had smoked less than 40-pack years (PY); and 
heavy smokers, who had smoked ≥40 PY [25]. PY are cal-
culated as the number of cigarettes smoked per day mul-
tiplied by the years of smoking, divided by 20 [26].
Echocardiography
Patients were imaged in the left lateral decubitus posi-
tion using a commercially available system equipped 
with a 3.5  MHz transducer. Two-dimensional grayscale, 
pulsed, continuous and color Doppler data were acquired 
from the parasternal and apical views. For tissue Doppler 
imaging, the sector width was adjusted to obtain a frame 
rate of at least 115 frames/s. Left ventricular ejection 
fraction (LVEF) was calculated using Simpson’s biplane 
technique [27].
Statistical analysis
The continuous variables are expressed as mean ± SD or 
as medians and interquartile ranges. The categorical vari-
ables between groups were compared using Chi-square 
tests. Hazard ratios with 95 % confidence intervals (95 % 
CIs) were used to estimate the adjusted relative risk for 
the various groups. Kaplan–Meier survival curves were 
Fig. 1 Flowchart for participants involved in the present study
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compared using the log-rank test. Multivariate Cox pro-
portional hazards regression models were applied to 
adjust for any confounding variables among groups. The 
analyses were conducted using SPSS (version 16.0, SPSS 
Inc., Chicago, IL, USA), and all tests were two sided. A p 
value <0.05 was used to determine statistical significance.
Results
Characteristics of the study population
The cohort consisted of 1118 patients with DCM: 300 
(26.8 %) women and 818 (73.2 %) men, with a mean age 
of 51.2 ± 14.6 years. Among the 1118 patients, those of 
Han nationality were 1074 (96.1 %), while minor nation-
ality were 44 (3.9 %); patients who lived in the north of 
the Yazi River were 970 (86.8 %) and those who lived in 
the south of the Yazi River were 148 (13.2  %). Of these 
subjects, 53.1  % (n  =  593) were non-smokers, 14.2  % 
(n  =  159) were mild-to-moderate smokers and 32.7  % 
(n  =  366) were heavy smokers. In terms of drinking, 
66.9 % (n = 747) of the cohort were non-drinkers; 12.7 % 
(n = 142) were mild drinkers and 20.5 % (n = 229) were 
moderate drinkers. Table 1 summarizes the baseline clin-
ical characteristics of the cohort. Among the patients in 
the smoker and non-smoker groups, fewer women were 
smokers; a history of atrial fibrillation was more com-
mon among the heavy smokers; higher blood pressure 
and circulating creatinine levels and a greater P duration 
and left ventricle diameter were observed in the mild-to-
moderate smokers and heavy smokers; and a larger right 
ventricle and left atrium diameter were observed in the 
heavy smokers. Among the patients in the non-drinker, 
mild-drinker and moderate-drinker categories, the num-
ber of women who were drinkers was lower, and a more 
frequent history of arterial hypertension, higher blood 
pressure levels and a larger left ventricle and left atrium 
diameter were observed in the moderate drinkers. There 
was no significant difference in terms of drug treatment 
at admission among the smokers or drinkers.
Relationship between age, gender and all‑cause mortality
Of the 1118 patients studied, 262 (23.4  %) died and 3 
(0.26  %) underwent heart transplantation during the 
mean follow-up of 3.5 ± 2.3 years. The all-cause mortal-
ity rates showed no difference between the non-smoker, 
mild-to-moderate-smoker and heavy-smoker groups 
(23.8, 20.8 and 24  %, respectively; log-rank χ2  =  1.281, 
P  =  0.527). There was also no significant difference in 
mortality between the non-drinker, mild-drinker and 
moderate-drinker groups (23.7, 23.2 and 22.3 %, respec-
tively; log-rank χ2 = 2.343, P = 0.310) (Fig. 2).
To determine whether smoking confers different 
degrees of risk between the different levels of drink-
ers with DCM, the entire cohort was divided into three 
subgroups and then further stratified according to the 
patients’ status as non-smokers, mild-to-moderate smok-
ers and heavy smokers. In the non-drinking patients, 
the all-cause mortality rates for non-smokers, mild-to-
moderate smokers and heavy smokers were 24.3, 22.1 
and 22.5  %, respectively; among the mild drinkers, the 
all-cause mortality rates for non-smokers, mild-to-mod-
erate smokers and heavy smokers were 18.2, 17.9 and 
28.6  %, respectively; and in the moderate drinkers, the 
all-cause mortality rates for non-smokers, mild-to-mod-
erate smokers and heavy smokers were 18.9, 20.6 and 
23.4  %, respectively. There was no significant difference 
in all-cause mortality between the subgroups of patients 
with different drinking statuses according their differ-
ent smoking statuses (log-rank χ2  =  1.286, P  =  0.526) 
(Fig. 3).
Cox proportional hazard models
When the clinical, laboratory, electrograph and electro-
cardiographic data were considered, univariate analysis 
revealed that age, history of hypertension, ventricular 
premature beat, New York Heart Association (NYHA) 
functional class, systolic blood pressure, diastolic blood 
pressure, P duration, QRS duration, left ventricle diam-
eter, LVEF, right ventricle diameter, left atrium diam-
eter, NT-pro-BNP, serum bilirubin, blood urea nitrogen, 
creatinine and fasting blood glucose were significant 
predictors of all-cause mortality in patients with DCM. 
Neither the smoking (HR 0.971, P = 0.663) nor the drink-
ing status (HR 0.891, P = 0.140) was included in the Cox 
analysis. After adjustment for age, gender, smoking and 
drinking status, disease course, right ventricle and left 
atrium diameter, LVEF and serum creatinine, Cox multi-
variate analysis showed that ventricular premature beats, 
systolic blood pressure at admission, QRS duration, left 
atrium diameter and fasting blood glucose were powerful 
independent predictors of all-cause mortality in patients 
with DCM. Neither smoking nor drinking was found to 
be a predictor of all-cause mortality in the present study 
(Table 2).
Discussion
In this large-scale sample cohort study, we investigated 
the associations between smoking, drinking and all-cause 
mortality in patients with DCM. Our findings suggested 
that there was no predictive value of smoking and drink-
ing for all-cause mortality in DCM patients; neither 
smoking nor drinking was an independent predictor of 
the all-cause mortality in patients with DCM.
Previous studies have found that that heavy drink-
ers exhibit a lower ejection fraction, greater end-
diastolic volume, increased left atrial dimensions and 
increased left ventricular wall thickness, which occur in a 
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Age (years) 51.2 ± 14.6 51.0 ± 16.4 49.6 ± 13.9 52.1 ± 11.5 0.184 51.4 ± 15.8 50.4 ± 13.0 50.7 ± 11.2 0.650
Female gender, 
n (%)




2 (0.5–6) 3 (0.65–7) 2 (0.25–6) 3 (0.5–6) 0.167 2 (0.5–6) 2 (0.325–5) 3 (0.93–7) 0.224




300 (26.8) 142 (23.9) 48 (30.2) 110 (30.1) 0.068 178 (23.8) 41 (28.9) 81 (35.4) 0.002
  Diabetes 
mellitus, 
n (%)
161 (14.4) 84 (14.2) 23 (14.5) 54 (14.8) 0.968 108 (14.5) 18 (12.7) 35 (15.3) 0.783
 Stroke, n (%) 51 (4.6) 27 (4.6) 6 (3.8) 18 (4.9) 0.846 38 (5.1) 5 (3.5) 8 (3.5) 0.490
 Atrial fibrilla-
tion, n (%)








216 (19.3) 120 (20.2) 24 (15.1) 72 (19.7) 0.338 152 (20.3) 26 (18.3) 38 (16.6) 0.429
 NYHA class 
III and IV, 
n (%)
821 (73.4) 439 (74.0) 106 (66.7) 276 (75.4) 0.102 558 (74.7) 99 (69.7) 164 (71.6) 0.367
Admission vital signs
 SBP (mm Hg) 113.1 ± 17.8 111.3 ± 17.4 115.0 ± 16.2 115.4 ± 18.7 0.001 112.0 ± 17.7 115.8 ± 17.4 115.1 ± 17.8 0.012
 DBP (mm Hg) 72.5 ± 12.6 71.0 ± 12.3 75.2 ± 12.2 73.6 ± 13.0 <0.001 71.3 ± 12.6 74.2 ± 12.9 75.1 ± 12.2 <0.001
 Heart rate, 
beats/min
80.8 ± 17.4 81.3 ± 17.8 79.9 ± 16.8 80.8 ± 17.4 0.611 81.1 ± 17.4 79.3 ± 17.4 80.9 ± 16.5 0.546
Laboratory values at admission
 AST (IU/L) 26 (20–35) 25 (19–34.75) 28 (20.75–36) 25 (20–35) 0.969 26 (19–35) 25 (20–34) 27 (21–37) 0.422
 ALT (IU/L) 28 (19–45) 26 (18–43) 33 (22–58.5) 30 (20–45.5) 0.826 27 (19–44) 28 (20–45) 32 (22–47.75) 0.656


















5.61 ± 1.83 5.61 ± 1.90 5.71 ± 2.04 5.58 ± 1.58 0.763 5.61 ± 1.83 5.48 ± 2.04 5.67 ± 1.56 0.614
 TG (mmol/L) 1.56 ± 1.02 1.57 ± 1.06 1.60 ± 0.94 1.53 ± 0.98 0.736 1.54 ± 1.04 1.50 ± 0.81 1.67 ± 1.05 0.237
 CHO 
(mmol/L)
4.60 ± 1.11 4.56 ± 1.12 4.61 ± 1.14 4.66 ± 1.10 0.458 4.58 ± 1.12 4.62 ± 1.05 4.67 ± 1.20 0.545
 Creatinine 
(µmol/L)
92.8 ± 35.3 88.2 ± 34.7 98.2 ± 44.4 97.8 ± 30.6 <0.001 91.2 ± 38.2 94.7 ± 25.7 96.9 ± 29.9 0.082
 BUN (µmol/L) 7.98 ± 3.99 7.79 ± 3.71 8.15 ± 5.62 8.20 ± 3.56 0.264 7.96 ± 4.06 7.63 ± 2.63 8.24 ± 4.45 0.366






















 QRS duration 
(ms)
119.7 ± 30.9 119.9 ± 32.4 119.7 ± 27.9 119.2 ± 29.9 0.941 119.6 ± 30.9 119.1 ± 31.0 120.0 ± 30.8 0.963
 QT (ms) 405.8 ± 54.5 406.7 ± 55.7 406.9 ± 57.5 403.9 ± 51.1 0.727 406.4 ± 54.1 403.0 ± 47.9 404.8 ± 58.7 0.768
 P (ms) 107.5 ± 21.7 105.0 ± 21.1 110.0 ± 20.6 110.7 ± 22.8 0.002 106.3 ± 21.8 108.2 ± 20.3 111.4 ± 21.8 0.036
 PR (ms) 183.0 ± 33.0 183.0 ± 33.4 178.2 ± 32.6 185.2 ± 32.4 0.148 183.0 ± 33.8 182.5 ± 32.8 183.5 ± 30.6 0.965





















 LVd (mm) 68.1 ± 9.4 67.3 ± 9.15 69.2 ± 9.10 69.1 ± 9.76 0.004 67.6 ± 9.27 69.6 ± 9.80 69.0 ± 9.40 0.020
 LVEF (mm) 31.9 ± 8.4 31.5 ± 8.0 32.1 ± 8.9 32.3 ± 8.7 0.341 31.6 ± 8.2 32.1 ± 8.6 32.7 ± 9.0 0.232
 RV (mm) 23.6 ± 5.4 23.3 ± 5.2 23.0 ± 4.7 24.5 ± 5.8 0.004 23.5 ± 5.4 23.9 ± 4.9 23.8 ± 5.7 0.583
 LA (mm) 44.0 ± 7.7 43.2 ± 7.6 43.9 ± 7.9 45.4 ± 7.6 <0.001 43.6 ± 7.5 44.7 ± 8.6 45.1 ± 7.5 0.020
Medications at admission
 Diuretics, n 
(%)
1085 (94.6) 562 (94.8) 151 (95.0) 345 (94.3) 0.925 706 (94.5) 130 (91.5) 222 (96.9) 0.079
 ACEI/ARB, n 
(%)
947 (84.7) 500 (84.3) 137 (86.2) 310 (84.7) 0.848 623 (83.4) 125 (88.0) 199 (86.9) 0.218
 Beta-blockers, 
n (%)
1015 (90.8) 537 (90.6) 151 (95.0) 327 (89.3) 0.118 677 (90.6) 129 (90.8) 209 (91.3) 0.958
 Digoxin, n (%) 898 (80.3) 486 (82.0) 124 (78.0) 288 (78.7) 0.593 587 (78.6) 118 (83.1) 193 (84.3) 0.111
 Spironolac-
tone, n (%)
1016 (90.9) 544 (91.7) 142 (89.3) 330 (90.2) 0.542 680 (91.0) 125 (88.0) 211 (92.1) 0.396
Data are expressed as mean ± SD, medians (interquartile range) or percentages; P values from independent-sample t tests are shown
Italics indicate P < 0.05
1 patient lacked drinking status data; 22 lacked electrocardiogram data; 43 lacked echocardiography data; 334 lacked NT-pro-BNP levels; 47 lacked fasting blood 
glucose levels; 29 lacked creatinine data; 40 lacked BUN levels; 83 lacked triglyceride data and total cholesterol levels; 71 lacked AST data; 72 lacked ALT data; 72 
lacked TB data; 74 lacked DB data; and 17 lacked data on the medications at admission
NYHA New York Heart Association, SBP systolic blood pressure, DBP diastolic blood pressure, AST aspartate aminotransferase, ALT alanine aminotransferase, BUN blood 
urea nitrogen, TG triglyceride, TC total cholesterol, BUN blood urea nitrogen, TB total bilirubin, DB direct bilirubin, BUN blood urea nitrogen, NT-pro-BNP N-terminal 
fragment pro-brain natriuretic peptide, LV left ventricle, LA left atrium, LVEF left ventricular ejection fraction, ACEI angiotensin-converting enzyme inhibitor, ARB 
angiotensin receptor blocker
Table 2 Cox regression of all-cause mortality in patients with DCM
The variables analyzed in the multivariate Cox mode included age, gender, ventricular premature beat, drinking and smoke status, disease duration, NYHA functional 
classes, systolic blood pressure, QRS duration, left ventricular, right ventriclular and left atrium diameter, LVEF, FBG and creatinine
Italics indicate P < 0.05
Variable Univariate analysis Multivariate analysis
HR 95 % CI P value I HR 95 % CI P value
Age 1.010 1.001–1.019 0.024 1.004 0.991–1.016 0.558
Sex 1.121 0.855–1.469 0.408 1.275 0.871–1.867 0.212
Ventricular premature beat 1.462 1.145–1.868 0.002 1.358 1.020–1.807 0.036
NYHA functional class 1.592 1.350–1.877 <0.001 1.223 0.990–1.511 0.062
Disease duration 1.028 1.011–1.044 0.001 1.012 0.990–1.035 0.291
Smoker 0.908 0.712–1.158 0.436 0.911 0.649–1.279 0.591
Drinker 0.817 0.630–1.060 0.129 0.951 0.669–1.352 0.779
Systolic blood pressure 0.982 0.975–0.989 <0.001 0.984 0.975–0.994 0.001
QRS duration 1.009 1.006–1.013 <0.001 1.010 1.005–1.014 <0.001
Left ventricle 1.037 1.025–1.050 <0.001 1.003 0.983–1.022 0.796
Right ventricle 1.061 1.037–1.086 <0.001 1.015 0.986–1.045 0.328
Left atrium 1.055 1.040–1.071 <0.001 1.047 1.025–1.069 <0.001
LVEF 0.963 0.948–0.978 <0.001 0.980 0.961–1.001 0.059
NT-pro-BNP 1.045 1.024–1.067 <0.001
FBG 1.097 1.041–1.156 <0.001 1.097 1.026–1.173 0.006
Creatinine 1.004 1.002–1.007 0.001 1.003 1.000–1.006 0.053
Page 6 of 8Li et al. Eur J Med Res  (2015) 20:78 
dose-dependent fashion and precede the onset of clinical 
symptoms or physical findings [28, 29]. The mechanisms 
underlying alcohol-induced myocardial damage include 
cardiac myocyte apoptosis [30], alterations in the exci-
tation–contraction coupling in cardiac myocytes [31], 
and increased oxidative stress [32] and activation of the 
renin–angiotensin system and the sympathetic nervous 
system [33]. However, moderate alcohol consumption has 
been proposed to confer protection against cardiovascu-
lar events while also increasing high-density lipoprotein 
cholesterol, decreasing platelet aggregation and coagu-
lation, enhancing endothelial function, reducing inflam-
mation, promoting antioxidant effects and decreasing the 
activity of angiotensin II (Ang II) [34–36]. In the present 
large-sample cohort study, although heavy drinkers were 
excluded owing to alcoholic cardiomyopathy, no signifi-
cant differences were found between patients who were 
Fig. 2 Kaplan–Meier survival curves for the smoking- and drinking-
related groups of patients with dilated cardiomyopathy. The upper 
panel shows the survival curves among the non-smoker, mild-to-
moderate-smoker and heavy-smoker groups (23.8, 20.8 and 24 %; 
log-rank χ2 = 1.281, P = 0.527). The lower panel shows the survival 
curves among the non-drinker, mild-drinker and moderate-drinker 
groups (23.7, 23.2 and 22.3 %; log-rank χ2 = 2.343, P = 0.310)
Fig. 3 Kaplan–Meier survival curves for patients with DCM who were 
drinkers, stratified by their status as non-smokers, mild-to-moderate 
smokers and heavy smokers (log-rank χ2 = 1.286, P = 0.526)
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non-drinkers, mild drinkers and moderate drinkers. In a 
study in patients with a previous myocardial infarction, 
those who consumed small-to-moderate amounts of 
alcohol exhibited a lower total mortality [10]. However, 
the present study found no favorable effect of mild-to-
moderate drinking on the all-cause mortality in the DCM 
patients.
Tobacco smoking has been solidly implicated in the 
etiology of cardiovascular diseases such as coronary 
artery disease, aortic aneurysm, stroke and periph-
eral vascular diseases [37], as cigarette smoking has 
been associated with higher serum levels of choles-
terol, coronary vasomotor reactivity, platelet aggrega-
tion, and a prothrombotic state [38–41]. Additionally, 
an association between smoking and cardiomyopathy 
has been suggested by the results of several animal stud-
ies [42–44]. Possible mechanisms underlying the asso-
ciation between smoking and cardiomyopathy include 
direct damage to cardiac muscles (following damage to 
the myocardial mitochondria) and an increase in car-
diac susceptibility to viral infections [43, 45]. Although 
it is well known that smoking increases cardiovascular 
morbidity and mortality [15, 16], the effect of smoking 
on the mortality of DCM patients cannot be conclu-
sively determined based on the available data [19–22]. 
In the present study, there was no detectable influence 
of mild-to-moderate smoking and heavy smoking on the 
all-cause mortality in DCM patients. Although the all-
cause mortality rate was lower among mild-to-moderate 
smokers than among non-smokers, this association did 
not achieve statistical significance.
Conclusion
In conclusion, there were no significant differences in 
mortality between the smoking- and drinking-related 
patient groups, indicating no effect of smoking and 
drinking on all-cause mortality in patients with DCM in 
the present large-scale study.
Limitations
The present study has several limitations. Like all hos-
pital-based cohorts, the examined study population was 
a selected population of patients who had been referred 
for treatment. Because the NT-pro-BNP test was not 
commonly used until the later years of this study and its 
results were missing in 334 patients, we excluded NT-
pro-BNP data from the multivariate Cox analysis to avoid 
the inclusion of potential confounding variables in the 
statistical analyses. Additionally, 14.1  % of the patients 
(n = 158) were lost to follow-up because of factors such 
as a lack of communication in rural areas; however, the 
main outcomes were not changed when we detected the 
losers in the Kaplan–Meier survival and Cox analyses. 
Ideally, all patients with DCM should be confirmed to 
be free of coronary artery disease. In practice, however, 
coronary arteriography is not routinely performed in all 
patients with congestive heart failure. Because retrospec-
tive studies cannot control the conditions under which 
patients are recruited or investigated, there was a very 
small subgroup of ischemic heart disease patients in the 
present study compared with the expected rates based on 
the numbers of patients who were subjected to coronary 
artery angiography, coronary CT scans or cardiac radio-
nuclide imaging at other hospitals, as only 334 patients 
underwent coronary artery angiography and only 80 
showed positive results at our hospital.
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